TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03279120
Drug: TFV/LNG IVR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used for 90 days (Continuous or Interrupted)
Study: NCT03279120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used for 90 days (Continuous or Interrupted)
Study: NCT03142282
Drug: maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: National Comprehensive Cancer Network (NCCN) or European Society for Medical Oncology (ESMO) suggested maintenance chemotherapy regimens: xeloda, bevacizumab
Study: NCT00138723
Drug: SPM 907
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00145106
Drug: Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01757795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be intravenously administered
Study: NCT02777866
Drug: Placebo: Infiltration of 0.9% Saline Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
Study: NCT02549391
Drug: KHK7580
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT02549391
Drug: KRN1493
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT03329638
Drug: Placebo Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Ophthalmic Solution dosed once daily for 12 months
Study: NCT03519295
Drug: MPDL3280A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPDL3280A administered every 2 weeks at 800 mg for 12 months.
Study: NCT03519295
Drug: mDCF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5-FU at 1200 mg/m2/day for 2 days) every 2 weeks
Study: NCT00565292
Drug: MK0859
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00602472
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to linagliptin 5 mg
Study: NCT01189409
Drug: PEG then Senna
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped bowel protocol with PEG for 3 weeks followed by senna for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
Study: NCT01189409
Drug: Senna then PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped bowel protocol with senna for 3 weeks followed by PEG for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
Study: NCT04446104
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc tablet 80 mg/vitamin C 500mg daily for 42 days
Study: NCT00475956
Drug: AZD2171
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet multiple ascending doses 20, 30 or 45 mg
Study: NCT00475956
Drug: AZD0530
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet multiple ascending doses 125 mg or 175 mg
Study: NCT00751608
Drug: APL180
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00751608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01908803
Drug: AL-60371/AL-817 otic suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01715740
Drug: Chinese Herbal Medicine (CHM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each CHM capsule, weighing 500mg, consists of XFS 250 mg and QSFFT 250 mg.
Study: NCT01715740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated powder with similar taste, color, odor to intervention Chinese herbal medicine
Study: NCT02004041
Drug: VLY-686
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02004041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01502774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single intravenous bolus injection of Placebo
Study: NCT01291732
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of matching placebo
Study: NCT03335670
Drug: [68Ga]Pentixafor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor
Study: NCT04631250
Drug: 5-Aminolevulinic Acid-Containing Product in Cutaneous Dose Form
Normalized name: 5-aminolevulinic acid-containing product in cutaneous dose form
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Aminolevulinic Acid was applied to both sides of the face.
Study: NCT00910416
Drug: propofol, remifentanil, atracurium
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol, remifentanil, atracurium dosages are adapted according to clinician's judgment
Study: NCT00910416
Drug: propofol, remifentanil, atracurium, sevoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosages are adapted according to clinician's judgment
Study: NCT00885170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to odanacatib 50 mg tablets once weekly for 24 months
Study: NCT02303327
Drug: Androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
Study: NCT02282098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Colchicine
Study: NCT01371357
Drug: TEST 1
Normalized name: Bar Test 10% Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g/day of guanidinoacetic acid
Study: NCT01371357
Drug: TEST 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
Study: NCT01371357
Drug: TEST 4
Normalized name: urine phenaphthazine-pH test 4 X 15 feet MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
Study: NCT01230983
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01230983
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01230983
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01230983
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01230983
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IT
Study: NCT03674853
Drug: Wuling Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: take Wuling Capsule in experiment group for 2 months
Study: NCT03674853
Drug: Oryzanol
Normalized name: Oryzanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: take oryzanol in active comparator group for 2 months
Study: NCT02900378
Drug: LCZ696 (Sacubitril/Valsartan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (sacubitril/valsartan) was available in 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
Study: NCT02900378
Drug: Placebo of LCZ696 (Sacubitril/Valsartan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of LCZ696 (sacubitril/valsartan) was available to match 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
Study: NCT02070718
Drug: Standard Dose Kappa Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04686669
Drug: FOR-6219 capsule formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.
Study: NCT04686669
Drug: FOR-6219 tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.
Study: NCT00957827
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo BID for five days
Study: NCT01018680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken by mouth, once daily for 10 weeks
Study: NCT00003701
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003701
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02196636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, administered orally with approximately 240 mL of buffer
Study: NCT02196636
Drug: RO6806127
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally with approximately 240 mL of buffer
Study: NCT00257985
Drug: GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00768456
Drug: Isotonic NaCl
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local Infiltration with NaCl
Study: NCT03441815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03281200
Drug: L - Antineoplastic and immunomodulating agents
Normalized name: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: L - Antineoplastic and immunomodulating agents
Study: NCT03281200
Drug: L01 - Antineoplastic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: L01 - Antineoplastic agents
Study: NCT06369727
Drug: MOB015B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topcal formulation
Study: NCT06369727
Drug: MOB015B vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topcal formulation
Study: NCT06369727
Drug: Negative irritant solution of 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control
Study: NCT04514653
Drug: Local Steroid
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local steroid
Study: NCT04514653
Drug: Topical Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid
Study: NCT06090136
Drug: TPN171H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg TPN171H tablets，single dose,oral
Study: NCT00483977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: oral for 2 weeks.
Study: NCT02902861
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate 50 mg/ml in syringes for sub-cutaneous injection; Once weekly (every 7 days) s.c. administration of 17.5 mg MTX; If PASI50 is not reached after 8 weeks, the dosing will be increased to 22.5 mg
Study: NCT02902861
Drug: Placebo ( for Methotrexate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl-Solution manufactured to mimic Methotrexate
Study: NCT04178785
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio.
Study: NCT01932801
Drug: XR-NTX
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03532204
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: At investigator's discretion
Study: NCT02353975
Drug: SHR3824
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.
Study: NCT04355169
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT00135551
Drug: thiazide diuretics
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: benidipie+thiazide diuretics, titlation scheme
Study: NCT01586572
Drug: mOPV1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.
Study: NCT01586572
Drug: bOPV 1,3
Approvals — FDA: no, EMA: no, PMDA: no
Description: The bivalent vaccine containing at least 106 CCID50 of Sabin poliovirus type 1 and 105•8 CCID50 of Sabin poliovirus type 3.
Study: NCT01021891
Drug: Technosphere®/Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02460419
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT03714880
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of study medication vs placebo
Study: NCT03068585
Drug: Neovasculgen (Cambiogeneplasmid)
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment
Study: NCT03695367
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.
Study: NCT03695367
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen, 600 mg.
Study: NCT03695367
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, 1 g.
Study: NCT03695367
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative IV ketorolac.
Study: NCT00559819
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (orange juice), same volume as alcohol
Study: NCT04465916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT04465916
Drug: Nucleotide analogue (Entecavir or Tenofovir Disoproxil)
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT01809743
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
Study: NCT03519711
Drug: PTC923
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC923 will be administered per dose and schedule specified in arm description.
Study: NCT01497561
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
Study: NCT04961684
Drug: Loceryl 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: One application per week for 3 months
Study: NCT01397968
Drug: YKP3089
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, dose to be titrated Tablet, dose to be titrated
Study: NCT01397968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule Placebo tablet
Study: NCT00057720
Drug: doxorubicin HCl liposome injection
Normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05754242
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 gr of ascorbic acid
Study: NCT05754242
Drug: 0.9% Saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 0.9% saline solution
Study: NCT01287741
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
Study: NCT01287741
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
Study: NCT02930018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: Placebo
Study: NCT01518894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution Q24 hours for 14 days
Study: NCT02593331
Drug: BFKB8488A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
Study: NCT03085940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00381602
Drug: GHRP-1/AG 70 mg depot in ESRD
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01987453
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT03383406
Drug: Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every cycle(4weeks)~Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1\~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1\~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1\~Day3 by Intravenous infusion.
Study: NCT00198107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
Study: NCT03626337
Drug: Thiamine 100 MG/ML
Normalized name: thiamine 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg thiamine provided as intramuscular injection
Study: NCT00934661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
Study: NCT00602082
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04575935
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive standard of care chemotherapy
Study: NCT02232906
Drug: intravenous ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) dose of 1,000 mg iron, followed by a 6-month ESA/FCM maintenance regimen (target: Hemoglobin 120 g/L, transferrin saturation \>20%)
Study: NCT00110747
Drug: S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
Study: NCT00110747
Drug: Placebo Peel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peel was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
Study: NCT00364104
Drug: Quadruple sequential Helicobacter pylori eradication + iron sulfate
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
Study: NCT00364104
Drug: Quadruple sequential Helicobacter pylori eradication therapy
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
Study: NCT00364104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).
Study: NCT02132429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo containing no active drug
Study: NCT02644421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04188561
Drug: Intra articular injection Group
Normalized name: meningococcal group B vaccine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients included in the study had been received 2 ml high molecular weight (1.476 x 106 average Daltons) hyaluronic acid with concentration of 22mg/ml (OPTIVISC UK hyaluronic acid for intra articular injection). Platelet rich plasma is arranged by withdrawing 10 ml of patient's personal venous blood, anticoagulant is added, and centrifuged by duo-spin method, at the rate of 3500 rpm for five minutes then injected twice with 2 weeks interval. 3 distinct layers are produced by the end of the centrifugation: plasma, buffy coat (platelet) and RBCs, about 3 - 3.5 ml of PRP is produced~at the end with platelet concentration of 1.4 - 1.6 million/μl on average.
Study: NCT01628666
Drug: Incremental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.
Study: NCT00510822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT01432730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets, BID
Study: NCT02822118
Drug: Chang'an I Recipe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.
Study: NCT02822118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
Study: NCT03108664
Drug: SYL1001 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in the affected eye
Study: NCT03108664
Drug: Vehicle opthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in the affected eye
Study: NCT02883400
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spironolactone 25 mg up to 50 mg
Study: NCT03195270
Drug: [18F]FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mCi of \[18F\]FDG via the antecubital vein in a bolus injection
Study: NCT00187005
Drug: L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description section for details of treatment interventions.
Study: NCT02032394
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
Study: NCT03315780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC